Potential of new NSAIDs as analgesics

Pain Reviews

Volumn 4, Issue 4, 1997, Pages 230-237

  Wallace, John L ^a   Calignano, Antonio ^b   Cirino, Giuseppe ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ACETYLSALICYLIC ACID; ANALGESIC AGENT; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; FLURBIPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ANALGESIC ACTIVITY; DRUG MECHANISM; DRUG SELECTIVITY; HYPERALGESIA; NONHUMAN; PAIN; REVIEW;

EID: 0031465677     PISSN: 09681302     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Ferreira S, Moncada S, Vane JR. Prostaglandins and the mechanism of analgesia produced by aspirin-like drugs. Br J Pharmacol 1973; 49: 86-97.
2. Lim RKS, Guzman F, Rodgers DW et al. Site of action of narcotic and non-narcotic analgesics determined by blocking bradykinin-evoked visceral pain. Arch Int Pharmacodyn 1964; 152: 25-57.
3. Tonussi CR, Ferreira SH. Mechanism of diclofenac analgesia: direct blockade of inflammatory sensitization. Eur J Pharmacol 1994; 251: 173-79.
4. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112: 1000-1016.
5. Flower RJ, Vane JR. Inhibition of prostaglandin synthetase in brain explains the anti-pyretic activity of paracetamol (4-acetamide-phenol). Nature 1972; 240: 410-11.
6. Whittle BJR, Higgs GA, Eakins KE, Moncada S, Vane JR. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 1980; 284: 271-73.
7. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692-96.
8. Vane JR, Mitchell JA, Appleton I et al. Inducible insoforms of cyclooxygenase and nitric oxide synthase in inflammation. Proc Natl Acad Sci USA 1994; 91: 2046-50.
9. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993; 90: 11693-97.
10. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268: 6610-14.
11. Xie W, Robertson DL, Simmons DL. Mitogen-inducible prostaglandin G/H synthase: a new target for nonsteroidal antiinflammatory drugs. Drug Dev Res 1992; 25: 249-65.
12. Jenner PN. A 12-month postmarketing surveillance study of nabumetone. A preliminary report. Drugs 1990; 40(suppl 5): 80-86.
13. Stroehmann I, Fedder M, Zeidler H. German drug monitoring studies with nabumetone. Drugs 1990; 40(suppl 5): 38-42.
14. Willkens RF. An overview of the long-term safety experience of nabumetone. Drugs 1990; 40(suppl 5): 34-37.
15. Paulus HE. FDA Arthritis Advisory Committee Meeting: serious gastrointestinal toxicity of nonsteroidal antiinflammatory drugs; drug-containing renal and biliary stones; diclofenac and carprofen approved. Arthritis Rheum 1988; 31: 1450-51.
16. Bellamy N, Bensen WG, Beaulieu A et al. A multicenter study of nabumetone and diclofenac SR in patients with osteoarthritis. J Rheumatol 1995; 22: 915-20.
17. Benhamou CL. Large-scale open trials with etodolac (Lodine®) in France: an assessment of safety. Rheumatol Int 1990; 10(suppl): 29-34.
18. Schattenkirchner M. An updated safety profile of etodolac in several thousand patients. Eur J Rheumatol Inflamm 1990; 10: 56-65.
19. Zvaifler N. A review of the antiarthritic efficacy and safety of etodolac. Clin Rheumatol 1989; 8: 43-53.
20. Balfour JA, Buckley MMT. Etodolac: a reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states. Drugs 1991; 42: 274-99.
21. Lemmel EM, Bolten W, Burgos-Vargas R et al. Efficacy and safety of meloxicam in patients with rheumatoid arthritis. J Rheumatol 1997; 24: 282-90.
22. Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug-enteropathy in rats: role of permeability, bacteria and enterohepatic circulation. Gastroenterology 1997; 112: 109-17.
23. Jeremy JY, Mikhailidis DP, Barradas MA et al. The effect of nabumetone and its principal active metabolite on in vitro human gastric mucosal prostanoid synthesis and platelet function. Br J Rheumatol 1990; 29: 116-19.
24. Melarange R, Gentry C, Durie M, O'Connell C, Blower PR. Gastrointestinal irritancy, anti-inflammatory activity, and prostanoid inhibition in the rat: differentiation of effects between nabumetone and etodolac. Dig Dis Sci 1994; 39: 601-608.
25. Russell RI. Endoscopic evaluation of etodolac and naproxen and their relative effects on gastric and duodenal prostaglandins. Rheumatol Int 1990; 19(suppl): 17-21.
26. Glaser K, Sung M-L, O'Neill K et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol 1995; 281: 107-11.
27. Chan CC, Gordon R, Brideau C et al. In vivo pharmacology of L-745,337: a novel non-steroidal antiinflammatory agent (NSAID) with an ulcerogenic sparing effect in rat and monkey stomach [Abstract]. Can J Physiol Pharmacol 1994; 72: 266.
28. Barner A. Review of clinical trials and benefit/risk ratio of meloxicam. Scand J Rheumatol 1996; 25(suppl 102): 29-37.
29. Seibert K, Zhang Y, Leahy K et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase-2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91: 12013-17.
30. Boyce S, Chan C-C, Gordon R et al. L-745,337: a selective inhibitor of cyclooxygenase-2 elicits antinociception but not gastric ulceration in rats. Neuropharmacology 1994; 33: 1609-11.
31. Hay CH, Trevethick MA, Wheeldon A, Bowers JS, De Belleroche JS. The potential role of spinal cord cyclooxygenase-2 in the development of Freund's complete adjuvant-induced changes in hyperalgesia and allodynia. Neuroscience 1997; 78: 843-50.
32. Stichtenoth DO, Wagner B, Frolich JC. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers. J Invest Med 1997; 45: 44-49.
33. Chan CC, Boyce S, Brideau C et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther 1995; 274: 1531-37.
34. Masferrer JL, Zweifel BS, Manning PT et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228-32.
35. Morham SG, Langenbach R, Loftin CD et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83: 473-82.
36. Slater DM, Berger LC, Newton R, Moore GE, Bennett PR. Expression of cyclooxygenase types 1 and 2 in human fetal membranes at term. Am J Obstet Gynecol 1995; 172: 77-82.
37. Onoe Y, Miyaura C, Kaminakayashiki T et al. IL-13 and IL-14 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J Immunol 1996; 156: 758-64.
38. Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 1996; 98: 2076-85.
39. Mizuno H, Sakamoto C, Matsuda K et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112: 387-97.
40. Kubes P, Wallace JL. Nitric oxide as a mediator of gastrointestinal injury - Say it ain't so. Med Inflamm 1995; 4: 397-405.
41. Whittle BJR. Neuronal and endothelium-derived mediators in the modulation of the gastric microcirculation: integrity in the balance. Br J Pharmacol 1993; 110: 3-17.
42. MacNaughton WK, Cirino G, Wallace JL. Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. Life Sci 1989; 45: 1869-76.
43. Kitagawa H, Takeda F, Kohei H. Effect of endothelium-derived relaxing factor on the gastric lesion induced by HCl in rats. J Pharmacol Exp Ther 1990; 253: 1133-37.
44. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology 1994; 107: 173-79.
45. Wallace JL, Reuter B, Cicala C et al. A diclofenac derivative without ulcerogenic properties. Eur J Pharmacol 1994; 257: 249-55.
46. Reuter BK, Cirino G, Wallace JL. Markedly reduced intestinal toxicity of a declofenac derivative. Life Sci 1994; 55: PL1-PL8.
47. Cuzzolin L, Conforti A, Adami A et al. Anti-inflammatory potency and gastrointestinal toxicity of a new compound, NO-naproxen. Pharmacol Res 1995; 31: 61-65.
48. Davies NM, Roseth AG, Appleyard CB et al. NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther 1997; 11: 69-79.
49. Mitchell JA, Cirino G, Akarasereenont P, Wallace JL, Flower RJ, Vane JR. Flurbinitroxybutylester: a novel anti-inflammatory drug devoid of ulcerogenic activity, inhibits cyclo-oxygenase-1 and cyclo-oxygenase-2 [Abstract]. Can J Physiol Pharmacol 1994; 72: 270.
50. Wallace JL, Pittman QJ, Cirino G. Nitric oxide releasing NSAIDs: a novel class of GI-sparing anti-inflammatory drugs. In: Proznansky W ed. New molecular approaches to anti-inflammatory therapy. Basel: Birkauser-Verlag, 1995: 121-29.
51. Lawand NB, Willis WD, Westlund KN. Blockade of joint inflammation and secondary hyperalgesia by L-NAME, a nitric oxide synthase inhibitor. NeuroReport 1997; 8: 895-99.
52. Cuzzocrea S, Zingarelli B, Calapai G, Nava F, Caputi AP. Zymosan-activated plasma induces paw oedema by nitric oxide and proslaglandin production. Life Sci 1996; 60: 215-20.
53. Stadler P, Armstrong D, Margalith D et al. Diclofenac delays healing of gastroduodenal mucosal lesions: double-blind, placebo-controlled endoscopic study in healthy volunteers. Dig Dis Sci 1991; 36: 594-600.
54. Elliott SN, McKnight W, Cirino G, Wallace JL. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 1995; 109: 524-30.
55. Gorfine SR. Topical nitroglycerine therapy for anal fissures and ulcers. N Engl J Med 1995; 333: 1156-57.
56. Murrell GAC, Szabo C, Hannafin JA et al. Modulation of tendon healing by nitric oxide. Inflamm Res 1997; 46: 19-27.
57. Schaffer MR, Tantry U, Gross SS, Wasserkrug HL, Barbul A. Nitric oxide regulates wound healing. J Surg Res 1996; 63: 237-40.